Our Services
Medical Information
Helpful Resources
Published on: 4/24/2026
Ozempic can cause temporary hair thinning, typically due to rapid weight loss triggering telogen effluvium, nutrient deficiencies from reduced appetite, and metabolic changes. The good news: most people experience full regrowth within 6–12 months when diet, nutrient levels, and stress are properly managed.
Key factors to address include dietary adjustments, screening for vitamin and mineral deficiencies, and discussing medication alternatives with your doctor if hair loss persists.
Because hair thinning can stem from many overlapping causes — some medication-related, others tied to thyroid issues, iron levels, or hormonal shifts — it's worth ruling out what's actually driving your symptoms before making changes. A free, instant, online symptom check can help you understand what may be going on and guide your next steps with clarity and confidence.
Reviewed for medical accuracy: 07/10/2026
Quick answers
The most common questions people search after this page
Ozempic (semaglutide) has become a popular treatment for type 2 diabetes and weight management. While many patients see improvements in blood sugar control and body weight, some report an unexpected side effect: hair thinning or loss. In this article, we'll explore why Ozempic can cause hair loss, what the research says, and when you might consider switching medications.
Although clinical trials for Ozempic did not list hair loss as a common side effect, real-world reports and case studies point to several plausible mechanisms:
Rapid Weight Loss and Telogen Effluvium
Nutrient Deficiencies
Hormonal and Metabolic Shifts
Stress and Lifestyle Factors
While large-scale studies on Ozempic and hair loss are limited, insights come from related fields:
Overall, experts agree that hair loss in this context is usually temporary. Once the body adjusts or nutrient intake improves, hair often regrows within 6–12 months.
If you're taking Ozempic and notice changes in your hair, watch for:
Keep in mind that mild shedding is normal—most people lose 50–100 hairs per day. It becomes concerning when you see clumps or significant thinning over weeks.
Before deciding to switch medications, consider these practical steps:
Review Your Diet
Check for Deficiencies
Moderate Weight Loss Rate
Stress Management
Topical and Supportive Treatments
Ozempic offers significant benefits for many patients, but hair loss can be distressing. You might discuss alternative options with your healthcare provider if:
Potential alternatives include other GLP-1 agonists (e.g., Trulicity®, Victoza®), SGLT2 inhibitors, or DPP-4 inhibitors—each with its own risk profile. Never stop or switch medications without medical supervision.
If you're experiencing hair loss or other concerning symptoms while taking Ozempic, get personalized guidance with Ubie's free AI symptom checker to help you better understand what you're experiencing and prepare informed questions for your healthcare provider.
While hair loss alone is rarely life-threatening, certain symptoms alongside shedding warrant urgent care:
If you experience any of these, contact your healthcare provider or seek emergency care right away.
Your physician can help determine the root cause of hair loss and adjust your treatment plan. Be prepared to discuss:
Open communication ensures you get individualized advice and avoid unnecessary anxiety.
Above all, don't ignore persistent or severe hair loss. Speak to a doctor about anything that could be life-threatening or serious, and make sure your treatment aligns with your overall health goals.
(References)
* Miller DE, Putterman J, Shah B. Telogen effluvium associated with glucagon-like peptide-1 receptor agonists: A case series. *Dermatol Online J*. 2023 Jan 1;29(1). PMID: 36728096.
* Putterman J, Shah B. Hair Loss and Glucagon-Like Peptide-1 Receptor Agonists: A Narrative Review and Practical Considerations. *Dermatol Ther*. 2024 Jan;37(1):e16827. PMID: 38169622.
* Wilding JPH, Batterham RL, Blickwedehl J, Bækdal TA, Frias JP. Safety of semaglutide in patients with type 2 diabetes or obesity: an update. *Expert Opin Drug Saf*. 2022 Mar;21(3):369-383. PMID: 35081254.
* Singh S, Sunkara K, Veldanda K, Patel J, Alur R. Adverse Event Profile of Semaglutide: A Disproportionality Analysis of the FDA Adverse Event Reporting System. *Int J Clin Pharm*. 2024 Jan 12. PMID: 38210986.
* Strazzulla LC, Salian S, Shah S, Glick SA, Shah B. Telogen effluvium in patients undergoing bariatric surgery: a systematic review. *Obes Surg*. 2021 Jul;31(7):3208-3217. PMID: 33786851.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.